View More Recent Stories

May 6, 2025 09:35AM Stifel on Viridian Therapeutic (VRDN): 'Rapidly Transitioning to Commercial Stage Company'
May 6, 2025 07:33AM Viridian Therapeutics, Inc. (VRDN) Tops Q1 EPS by 11c
Apr 7, 2025 07:00AM Viridian Therapeutics (VRDN) Appoints Jeff Ajer to its Board
Apr 4, 2025 07:58AM Stifel Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Feb 27, 2025 07:13AM Viridian Therapeutics, Inc. (VRDN) Tops Q4 EPS by 22c
Jan 7, 2025 08:29AM Stifel Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Dec 17, 2024 09:16AM RBC on Viridian (VRDN): 'Compelling THRIVE-2 Data Could Change the Game for Chronic TED & VRDN'; PT Raised
Dec 17, 2024 06:52AM H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Dec 17, 2024 06:34AM Oppenheimer Reiterates Outperform Rating on Viridian Therapeutic (VRDN)
Dec 16, 2024 07:05AM Viridian Therapeutics (VRDN) Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
Nov 25, 2024 05:32AM TD Cowen Starts Viridian Therapeutic (VRDN) at Buy
Nov 14, 2024 06:57AM Viridian Therapeutic (VRDN) PT Raised to $34 at H.C. Wainwright
Nov 12, 2024 10:51AM Viridian Therapeutic (VRDN) PT Raised to $41 at Stifel
Nov 12, 2024 07:24AM Viridian Therapeutics, Inc. (VRDN) Misses Q3 EPS by 9c
Oct 28, 2024 07:19AM Needham Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Oct 28, 2024 06:04AM Goldman Sachs Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Sep 13, 2024 06:33AM Viridian Therapeutic (VRDN) PT Raised to $44 at RBC Capital
Sep 12, 2024 06:12AM Viridian Therapeutics (VRDN) Prices Upsized 10.67M Share Offering at $18.75/sh
Sep 12, 2024 05:07AM Viridian Therapeutic (VRDN) PT Raised to $31 at Goldman Sachs
Sep 11, 2024 07:12AM Viridian Therapeutic (VRDN) PT Raised to $38 at Needham
Sep 11, 2024 06:37AM H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Sep 11, 2024 06:25AM Viridian Therapeutic (VRDN) PT Raised to $22 at B.Riley
Sep 10, 2024 04:33PM After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics
Sep 10, 2024 04:01PM Viridian Therapeutics (VRDN) Announces Proposed $150M Share and Warrant Offering
Sep 10, 2024 01:08PM Viridian Therapeutic (VRDN) PT Raised to $40 at Stifel
Sep 10, 2024 11:41AM Viridian Therapeutic (VRDN) PT Raised to $56 at BTIG
Sep 10, 2024 07:02AM Viridian Therapeutics (VRDN) Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
Aug 30, 2024 07:35AM Needham Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Aug 14, 2024 03:58PM Goldman Sachs Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Jul 25, 2024 02:29PM Viridian Therapeutics (VRDN) September 15 puts active as share price trades $16.53
Jul 16, 2024 10:52AM H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Jul 15, 2024 01:23PM BTIG Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Jun 11, 2024 12:52PM Goldman Sachs Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Jun 11, 2024 12:47PM RBC Capital Reiterates Outperform Rating on Viridian Therapeutic (VRDN)
Jun 11, 2024 12:32PM BTIG Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Jun 11, 2024 05:02AM Wolfe Research Starts Viridian Therapeutic (VRDN) at Outperform
View More Recent Stories